Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 95,100 shares, an increase of 36.2% from the October 15th total of 69,800 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lifted their target price on Vivos Therapeutics from $6.40 to $6.60 and gave the company a “buy” rating in a research note on Tuesday, August 20th.

Vivos Therapeutics Stock Performance

VVOS stock opened at $3.02 on Friday. The company has a market capitalization of $14.39 million, a PE ratio of -0.44 and a beta of 7.71. The company’s fifty day moving average price is $2.79 and its 200-day moving average price is $2.52. Vivos Therapeutics has a one year low of $1.91 and a one year high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.60) EPS for the quarter. The company had revenue of $4.05 million during the quarter. Vivos Therapeutics had a negative return on equity of 652.32% and a negative net margin of 85.90%. On average, research analysts predict that Vivos Therapeutics will post -3.13 EPS for the current fiscal year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.